Table 1.

Characteristics of the study group (n = 261) and historical control group (n = 251)


Characteristic

Imatinib mesylate

Historical control

P
No.   261   251   NA  
Age at least 60 y   90 (34%)   42 (17%)   < .0001  
Splenomegaly   27 (10%)   36 of 170 (21%)   .003  
Mos from diagnosis to therapy    
    Median   33   26   .002  
    Less than 12   28 (11%)   41 (16%)   
    12 to 35   110 (42%)   130 (52%)   
    36 or more   123 (47%)   80 (32%)   
Hemoglobin level less than 12.0 g/dL   100 (38%)   127 of 241 (53%)   .002  
White blood cell count    
    Less than 10 × 109/L   135 (52%)   66 of 235 (28%)   < .0001  
    10 × 109/L to 50 × 109/L   102 (39%)   115 of 235 (49%)   
    More than 50 × 109/L   24 (9%)   54 of 235 (23%)   
Platelet count    
    450 × 109/L to 700 × 109/L   38 (15%)   30 of 240 (12%)   .42  
    More than 700 × 109/L   21 (8%)   27 of 240 (11%)   
Peripheral blasts present   45 (17%)   50 of 232 (22%)   .27  
Marrow blasts at least 5%   25 (10%)   16 of 182 (9%)   .91  
Peripheral basophils at least 7%   30 (11%)   31 of 233 (13%)   .64  
Marrow basophils at least 5%   33 (13%)   17 of 181 (9%)   .36  
Ph 90% or less before therapy   72 (28%)   22 of 186 (12%)   < .0001  
Additional chromosomal abnormalities other than Ph variants or loss of Y   24 (9%)   26 of 184 (14%)   .14  
IFN-α last response    
    Hematologic resistance   22 (8%)   51 (20%)   < .0001  
    Hematologic relapse   13 (5%)   24 (10%)   
    Cytogenetic resistance   126 (48%)   122 (49%)   
    IFN-α intolerance
 
100 (38%)
 
54 (22%)
 

 

Characteristic

Imatinib mesylate

Historical control

P
No.   261   251   NA  
Age at least 60 y   90 (34%)   42 (17%)   < .0001  
Splenomegaly   27 (10%)   36 of 170 (21%)   .003  
Mos from diagnosis to therapy    
    Median   33   26   .002  
    Less than 12   28 (11%)   41 (16%)   
    12 to 35   110 (42%)   130 (52%)   
    36 or more   123 (47%)   80 (32%)   
Hemoglobin level less than 12.0 g/dL   100 (38%)   127 of 241 (53%)   .002  
White blood cell count    
    Less than 10 × 109/L   135 (52%)   66 of 235 (28%)   < .0001  
    10 × 109/L to 50 × 109/L   102 (39%)   115 of 235 (49%)   
    More than 50 × 109/L   24 (9%)   54 of 235 (23%)   
Platelet count    
    450 × 109/L to 700 × 109/L   38 (15%)   30 of 240 (12%)   .42  
    More than 700 × 109/L   21 (8%)   27 of 240 (11%)   
Peripheral blasts present   45 (17%)   50 of 232 (22%)   .27  
Marrow blasts at least 5%   25 (10%)   16 of 182 (9%)   .91  
Peripheral basophils at least 7%   30 (11%)   31 of 233 (13%)   .64  
Marrow basophils at least 5%   33 (13%)   17 of 181 (9%)   .36  
Ph 90% or less before therapy   72 (28%)   22 of 186 (12%)   < .0001  
Additional chromosomal abnormalities other than Ph variants or loss of Y   24 (9%)   26 of 184 (14%)   .14  
IFN-α last response    
    Hematologic resistance   22 (8%)   51 (20%)   < .0001  
    Hematologic relapse   13 (5%)   24 (10%)   
    Cytogenetic resistance   126 (48%)   122 (49%)   
    IFN-α intolerance
 
100 (38%)
 
54 (22%)
 

 

NA indicates not applicable.

or Create an Account

Close Modal
Close Modal